Sulfonamide inhibitors: a patent review 2013-present

GÜLÇİN İ., TASLIMI P.

EXPERT OPINION ON THERAPEUTIC PATENTS, cilt.28, sa.7, ss.541-549, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 28 Sayı: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/13543776.2018.1487400
  • Dergi Adı: EXPERT OPINION ON THERAPEUTIC PATENTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.541-549
  • Anahtar Kelimeler: Sulfonamide, Tyrosine kinase, HIV-1 protease, Histone deacetylase 6, protein tyrosine phosphatase 1B, sphingosine kinase, pyrazole kinase, tyrosyl DNA phosphodiesterase, enzyme inhibitor, CHRONIC MYELOID-LEUKEMIA, TYROSINE KINASE INHIBITORS, DNA PHOSPHODIESTERASE I, HISTONE DEACETYLASE 6, CARBONIC-ANHYDRASE, BIOLOGICAL EVALUATION, PROTEASE INHIBITORS, PHOSPHATASE 1B, ACETYLCHOLINESTERASE, DERIVATIVES
  • Atatürk Üniversitesi Adresli: Evet

Özet

Introduction: Sulfonamide compounds are significant class of synthetic bacteriostatic antibiotics still which used today for the therapy of bacterial infections and those caused by other microorganisms. They are also known as sulfa drugs and were the main source of therapy against bacterial infections before the introduction of penicillin in 1941. Additionally, The first sulfonamide section is present inmany clinically used drugs such as diuretics, carbonic anhydrase inhibitors and antiepileptics.